Axon: 1 Nasdaq 100 Compounder to Buy, vs. Intel and Texas Instruments to Skip

Axon has the strongest Nasdaq 100 growth setup in this group

Axon just posted revenue up 35% and raised its full-year growth outlook to 32% to 34%. In this comparison, it looks like the cleanest compounder among these Nasdaq 100 names.

Better growth, better mix

Axon's quarter was strong across more than just the top line. Software & Services revenue increased 36% year over year to $398 million, annual recurring revenue grew 39% to $1.6 billion, and net revenue retention reached 126%. That matters because it points to a business becoming less dependent on standalone hardware units and more embedded in recurring workflows.

Why the timing matters

Axon also just delivered its 10th consecutive quarter of revenue growth above 30%. Forward indicators remained healthy too: future contracted bookings grew 41% year over year to $15.1 billion. For investors looking for fresh execution rather than an old recovery narrative, that is the stronger setup.

Bull case versus the alternatives

The bull case is straightforward: Axon is still compounding quickly, while the business mix is shifting toward higher-value recurring revenue. The main risk is that public-safety spending can slow and the current valuation leaves less room for disappointment. But compared with Intel's strongest revenue growth in more than fifteen years or Texas Instruments' return to broad growth, Axon still offers the best combination of speed, stickiness, and rerating potential right now.

Intel's quarter improved, but the turnaround is not proven

Intel's latest report was much better than the bearish case, yet one strong quarter is not enough to prove a business-model reset.

The quarter improved; the longer-term economics still need proof

Intel's Q2 results were clearly better than feared: revenue reached $16.1 billion, up 25% year over year, and non-GAAP EPS was $0.42. Management also highlighted higher factory yields and improved cycle times, while saying AI-driven compute continues to strengthen across its product and foundry businesses.

That is why the bull case exists. But the longer-term record still weighs on the story. Intel's sales have tumbled by 4.9% annually over the last five years, and the company still has negative free cash flow. For a capital-intensive semiconductor business, that means the recovery story still depends on years of execution rather than one strong quarter.

What investors need to see next

Intel becomes more credible only if several quarters of results show that growth is broadening and investments are starting to translate into better cash returns. Management is already meaningfully increasing its investments in equipment, clean room space, and substrates, so the burden of proof is still on durability. Until that shows up, the stock looks more like a turnaround trade than a proven long-term compounder.

Texas Instruments is recovering, but Axon still has more upside here

Texas Instruments has a real recovery story, but against Axon, the opportunity looks less compelling.

The rebound is genuine

TI's rebound is legitimate. Q2 revenue reached $5.46 billion and rose 23% year over year. Management also guided to $5.65 billion to $6.15 billion for Q3. The recovery was broad enough to matter: industrial demand recovered, data center revenue doubled, and automotive re-accelerated, and bullish commentary noted the first price increases in years.

Why Axon still ranks higher

The issue with TI is not quality; it is opportunity cost. TI is improving from a weaker base in a more mature analog market, while Axon is still growing at 35% revenue growth and has re-guided to 32% to 34% full-year revenue growth. That does not make TI a bad business. It just means the highest-upside compounding setup in this group is Axon.

The main caution is valuation and timing

TI also appears to have already had part of its rerating. Recent coverage described the stock as trading in the mid-$220s after a sharp rebound, and bullish commentary on the quarter said the stock's strong run left little room for upside. If the recovery continues, TI can still work. But on risk-versus-reward here, Axon still looks like the cleaner setup.

The practical call: own Axon, keep TI on the radar, stay skeptical on Intel

In a Nasdaq 100 full of recovery stories and turning-point narratives, the clearest long-term idea in this group is Axon.

Own this one

• Axon: The business just had another record quarter, raised its full-year growth outlook, and is leaning harder into recurring revenue. Keep an eye on whether future contracted bookings stay strong.

Watch this next

• Texas Instruments: The recovery is real, with industrial demand recovered, data center revenue doubled, and automotive re-accelerated. It is worth monitoring, even if it is not the top buy here.
• Intel: Watch for proof, not headlines. Management says it is well-positioned for sustainable growth across our CPU franchise, ASICs, advanced packaging and vast wafer foundry network. Investors just need several quarters of evidence that this is sticking.

What would change the view

• Axon: The thesis weakens if the software mix stalls, the raised growth outlook slips, or growth stops looking broad-based.
• Intel: The story improves if growth broadens and cash generation improves alongside higher investment.
• Texas Instruments: The setup gets better if the recovery keeps broadening across industrial, data center and automotive.

In a hot index, the cleanest trade is not always the biggest turnaround. Sometimes it is the business that is still compounding at speed.